Objective: The results of treatment of brain tumours have been disappointing. The objective of this study was to evaluate a new treatment with antineoplastons A10 and AS2-1.
Patients and Methods: This study involved a cohort of patients who had failed established therapies and were treated in private practices in the USA and Australia. Patients received daily intravenous injections of antineoplastons A10 and AS2-1 at average dosages of 7.7 and 0.36 g/kg/day, respectively. Tumourdimensions were documented by magnetic resonance imaging. Changes in tumour size were categorised as defined by the National Cancer Institute.
Results: Antineoplastons A10 and AS2-1 eliminated or substantially reduced tumours in 44% of patients with brain tumours. Of the 36 évaluable patients, nine had a complete response, seven a partial response, and 12 stable disease. Progressive disease occurred in eight patients. 15 patients are alive today, 86.5% of them for over 3 years from the beginning of treatment. Complete and partial responses were documented in glioblastoma multiforme, astrocytoma, oligodendroglioma, mixed glioma, medulloblastoma, and malignant meningioma. Adverse drug experiences included easily treated abnormalities in plasma electrolytes. In a small percentage of patients additional adverse effects possibly related to antineoplastons included skin rash (19%), somnolence (17%), weakness (14%), nausea (6%), vomiting (3%), headaches (3%), slurred speech (6%), confusion (3%), fever (3%) and fluid retention (3%). Adverse effects were reversed on temporary discontinuation or dose reduction.
Conclusion: Antineoplaston therapy produced complete or partial responses in 16 of 36 (44%) patients with brain tumours. Compared with standard treatment, antineoplaston therapy is associated with prolonged survival time and prolonged time to disease progression.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Burzynski SR. Purified antineoplaston fractions and methods of treating neoplastic disease. US PatentNo. 4,470,970. 1984
Burzynski SR. Synthetic antineoplastons and analogs. Drugs Future 1986; 11: 679–88
Burzynski SR. Potential of antineoplastons in diseases of old age. Drugs Aging 1995; 7(3): 1 7-67
Hawkins MG, Friedman MA. National Cancer Institute’s evaluation of unconventional cancer treatments. J Natl Cancer Inst 1992; 84: 1699–702
Burzynski SR, Kubove E, Burzynski B. Phase II clinical trials of Antineoplastons A10 and AS2-1 infusions in astrocytoma. In: Adam D, Buchner T, Rubinstein E, editors. Recent advances in chemotherapy. Munich: Futuramed Publishers, 1991: 2506–07
Burzynski SR, Kubove E, Szymkowski B. Phase II clinical trials of Antineoplastons A10 and AS2-1 infusions in high grade glioma. Presented at the 18th International Congress of Chemotherapy; 1993 Jun 27–Jul 2: Stockholm, Sweden
Eriguchi N, Tsuda H, Hara H, et al. The effect of antineoplastons A10, AS2-1 on brain tumors. In: Adam D, Buchner T, Rubinstein E, editors. Recent advances in chemotherapy. Munich: Futuramed Publishers, 1991: 2504–5
Tsuda H, Sugita Y, Sugita N, et al. Effect of Antineoplaston AS2-1 on high grade glioma. Presented at the 18th International Congress of Chemotherapy; 1993 Jun 27–Jul 2: Stockholm, Sweden
Sugita Y, Tsuda H, Maruiwa H, et al. The effect of antineoplaston, a new antitumor agent, on malignant brain tumors. Kurume Med J 1995; 42: 133–40
Elias T. The Burzynski Breakthrough. Santa Monica, CA: General Publishing Group; 1997
Lerner M. Stanislaw Burzynski — antineoplastons on the edge of medical credibility. In: Lerner M, editor. Choices in healing. Cambridge, MA: MIT Press; 1994
Smith MEG. The Burzynski controversy in the United States and in Canada: a comparative case study in the sociology of alternative medicine. Can J Sociol 1992; 17: 133–60
Samid D, Sherman L, Rimoldi D. Induction of phenotypic reversion and terminal differentiation in tumor cells by antineoplaston AS2-1. Presented at the 9th International Symposium on Future Trends in Chemotherapy; 1990 March 26–28, Geneva, Switzerland
Samid D, Yeh TJ, Shack S. Interferon in combination with anti-tumorigenic phenyl derivatives: potentiation of α-IFN activity in vitro. Br J Haematol 1991; 79Suppl. 1: 81–3
Samid D, Shack S, Sherman LT. Phenylacetate: a novel non-toxic inducer of tumor cell differentiation. Cancer Res 1992; 52: 1988–92
Thibault A, Cooper MR, Figg WD, et al. Aphase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res 1994; 54: 1690–4
Thibault A, Samid D, Cooper MR, et al. Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer (Phila)1995; 75: 2932–8
Shack S, Chen LC, Miller AC, et al. Increased susceptibility of ras-transformed cells to phenylacetate is associated with inhibition of p2 lras isoprenylation and phenotypic reversion. Int J Cancer 1995; 63: 124–9
Adam L, Crepin M, Savin C, et al. Sodium phenylacetate induces growth inhibition and Bcl-2 down-regulation and apoptosis in MCF7 ras cells in vitro and in nude mice. Cancer Res 1995; 55: 5156–60
Liu L, Samid D. Mutant p53 as a target of phenylacetate in human glioblastoma. Presented at the 86th Annual Meeting of the American Association for Cancer Research; 1995 March 18–22; Toronto, Canada
Gorospe M, Shack S, Guyton KZ, et al. Up-regulation and functional role of p21 Wafl/Cipl during growth arrest of human breast carcinoma MCF-7 cells by phenylacetate. Cell Growth Differ 1996; 7: 1609–15
Sandberg-Wollheim M, Malmström P, Strömblad LG, et al. A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grade 3 and/or 4. Cancer 1991; 68: 22–9
Hildebrand J, Sahmoud T, Mignolet F, et al. Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. Neurology 1994; 44: 1479–83
Jeremic B, Grujicic D, Jevremovic S, et al. Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a Phase II study. J Clin Oncol 1992; 10: 1074–7
Couldwell WT, Hinton DR, Surnock AA, et al. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res 1996; 2: 619–22
Yung WKA, Kyritsis AP, Gleason MJ, et al. Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. Clin Cancer Res 1996; 2: 1931–5
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1953; 53: 457–81
Barker FG, Chang SM, Gutin PH, et al. Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 1998; 42: 709–20
Prados MD, Chang SM, Malec M, et al. Survival expectation following chemotherapy treatment for patients with GBM and anaplastic glioma (AG) at first relapse: a retrospective review of the UCSF database. Presented at the Society for Neuro-Oncology Meeting; 1999 Jan, San Francisco, CA, USA
60th Meeting of Oncologic Drugs Advisory Committee, FDA; 1999 Jan 12, Gaithersburg, MD, USA
About this article
Cite this article
Burzynski, S.R., Conde, A.B., Peters, A. et al. A Retrospective Study of Antineoplastons A10 and AS2-1 in Primary Brain Tumours. Clin. Drug Investig. 18, 1–10 (1999). https://doi.org/10.2165/00044011-199918010-00001
- Adis International Limited
- Glioblastoma Multiforme
- Primary Brain Tumour
- Clin Drug Invest
- Anaplastic Glioma